SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

Core Insights - SOPHiA GENETICS reported a fourth quarter revenue of $21.7 million, a 22% increase year-over-year, and a full-year revenue of $77.3 million, up 19% year-over-year, indicating strong growth momentum [1][2] - The company experienced an IFRS net loss of $19.2 million in Q4 2025, a 27% increase from the previous year, and a full-year net loss of $79.0 million, up 26% year-over-year [1][2] - Adjusted gross margin improved to 74.2% in FY 2025, reflecting a 140 basis point increase year-over-year, despite a 40% increase in total terabytes processed by the platform [1][2] Financial Performance - Q4 2025 IFRS net loss: $19.2 million, up 27% YoY; Adjusted EBITDA loss: $9.9 million, up 9% YoY [1] - FY 2025 IFRS net loss: $79.0 million, up 26% YoY; Adjusted EBITDA loss: $41.5 million, up 3% YoY [1] - Gross margin for Q4 2025: 67.7% reported, 73.9% adjusted; FY 2025 gross margin: 67.4% reported, 74.2% adjusted [1][2] Business Highlights - The company signed 124 new core genomics customers in FY 2025, a significant increase from 92 in FY 2024, and achieved a net dollar retention rate of 115% [1][2] - New customer signings included major health systems in the U.S. expected to analyze 60,000 patients annually [1][2] - The company performed over 391,000 analyses in FY 2025, with a record 105,000 analyses in Q4 2025 [1][2] Growth Drivers - Anticipated growth in 2026 will be driven by continued execution in the U.S. market, expansion of the Liquid Biopsy application MSK-ACCESS®, and renewed momentum in the BioPharma business [1][2] - The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [1][2] Strategic Collaborations - A strategic collaboration was announced with MD Anderson Cancer Center to co-develop advanced multimodal oncology testing solutions [1][2] - Continued partnerships with Myriad Genetics and A.D.A.M. Innovations aim to develop MSK-ACCESS® into a regulated global companion diagnostic assay [1][2]